Press "Enter" to skip to content

Hypopigmentation Disorder Treatment Market: Asia Pacific to be Highly Lucrative Market

Transparency Market Research (TMR) has published a new report titled, “Hypopigmentation Disorder Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.” According to the report, the global hypopigmentation disorder treatment market was valued at US$ 1,277.7 Mn in 2017 and is projected to expand at a high CAGR of 5.9% from 2018 to 2026. Rise in prevalence of hypopigmentation disorders across the world is anticipated to drive the global hypopigmentation disorder treatment market during the forecast period.

Asia Pacific and North America are projected to dominate the global hypopigmentation disorder treatment market during the forecast period. The market in these regions is primarily driven by increase in government initiatives and awareness about vitiligo and other hypopigmentation disorders. The market in Asia Pacific is anticipated to expand at a high CAGR from 2018 to 2026. The hypopigmentation disorder treatment market in North America is expected to expand at a moderate CAGR during the forecast period. The hypopigmentation disorder treatment market in Latin America is likely to grow at a moderate pace from 2018 to 2026.

The global hypopigmentation disorder treatment market is fragmented, owing to the presence of several small and large companies. However, the market is dominated by a few major players with strong global presence. The report provides profiles of leading players operating in the global hypopigmentation disorder treatment market. Key players in the market include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=47592

In terms of treatment, the topical drugs segment is projected to account for dominant share of the global hypopigmentation disorder treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2018 to 2026.

Dominance of the segment is attributed to increase in patient preference for topical drugs as the first line of treatment due to lower cost and higher efficacy. The chemical peels segment held major share of the market in 2017, followed by the topical drugs segment, due to increase in acceptance and popularity of chemical peels by dermatologists as well as patients. The laser therapy and microdermabrasion segments accounted for around 10.0% share of the global hypopigmentation disorder treatment market in terms of revenue in 2017.

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)